Cost-Effectiveness Analysis of Amifostine (Ethyol©) in Patients with Non-Small Cell Lung Cancer

REFERENCES

• Anonymous. Cancer Facts and Figures. American Cancer Society. Atlanta, GA, 2002; www. cancer. org, 2002.
   Google Scholar
• Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225S-233S.
   PubMedGoogle Scholar
• Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710–7.
   PubMed Web of Science ®Google Scholar
• Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr Probl Cancer 1991; 15: 61–104.
   PubMedGoogle Scholar
• Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995; 13: 253–67.
   PubMed Web of Science ®Google Scholar
• Raby B, Pater J, Mackillop W. A survey of Canadian physician's beliefs about the use of radiation and chemotherapy in non-small cell lung cancer (abstract 1079). Proc Am Soc Clin Oncol 1994; 13: 327.
   Google Scholar
• Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med 1988; 318: 612–7.
   PubMed Web of Science ®Google Scholar
• Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 330–40.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplati, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival. J Clin Oncol 1996; 14: 1913–21.
   Google Scholar
• Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–12.
   PubMed Web of Science ®Google Scholar
• Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of nonsmall-cell lung cancer: A randomised phase II study. Br J Cancer 1995; 72: A1551–5.
   PubMedGoogle Scholar
• Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134–40.
   PubMed Web of Science ®Google Scholar
• Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol 1996; 23: 83–9.
   PubMed Web of Science ®Google Scholar
• Wadler S, Goldberg G, Fields A, et al. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Semin Oncol 1996; 23: 64–8.
   PubMedGoogle Scholar
• 2001 Drug Topics Red Book: Medical Economics Company; Montvale, NJ, 2001.
   Google Scholar
• Bennet C, Golub R, Calhoun E. Cost-utility assessment of amifostine as firstline therapy for ovarian cancer. Int J Gynecol Cancer 1998; 8: 64–72.
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13: 322–38.
   PubMed Web of Science ®Google Scholar
• Looney S. A phase II trial of amifostine with paclitaxel, carboplatin, and concurrent radiation therapy for unresectable non-small cell lung cancer (abstract 1922). ASCO meeting abstracts, 1998.
   Google Scholar
• Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 3038–47.
   PubMed Web of Science ®Google Scholar
• Budman D, Rosner G, Lichtman S, et al. Evaluation of amifostine as a chemoprotective agent in combination with cyclophosphamide and molgamostim (GM-CSF). Cancer Ther 1998; 1: 164–167.
   Google Scholar
• Detsky A, Naglie G. A clinician's guide to cost-effective analysis. Ann Intern Med 1990; 113: 150–158.
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473–81.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection. Support Care Cancer 1997; 5: 489–99.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333–55.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Muers MF, Peake MD, et al. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. Br J Cancer 2001; 84: 19–24.
   PubMedGoogle Scholar
• Perng RP, Chen YM, Ming-Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997; 15: 2097–102.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860–70.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133–41.
   Google Scholar
• Manegold C, Drings P, von Pawel J, et al. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. Semin Oncol 1997; 24: S8-13-S8-17.
   Google Scholar